Citations

Clear

42 citation(s) found for "Scholz, D".

Smartphone Passive Digital Phenotyping in Frontotemporal Lobar Degeneration
Paolillo, Emily W. , Dhanam, Sreya , Taylor, Jack C. , Sanderson-Cimino, Mark, Fregly, Ray, Saloner, Rowan, Casaletto, Kaitlin B, Kramer, Joel H, Miller, Bruce L, Seeley, William W, Gorno-Tempini, Maria Luisa, Ljubenkov, Peter A. , Rojas, Julio C, Lee, Suzee, Sturm, Virginia, Appleby, Brian, Bayram, Ece, Clark, David, Considine, Ciaran , Darby, R. Ryan , Day, Gregory S, Vito, Alyssa , Eldaief, Mark, Fields, Julie A. , Ghoshal, Nupur , Huey, Edward D, Irwin, David J, Kantarci, Kejal, Kwan, Justin , Mackenzie, Ian R. , Masdeu, Joseph C, Onyike, Chiadi U, Pantelyat, Alexander, Pascual, Belén , Popli, Tanav, Rascovsky, Katya, Rezaii, Neguine , Scholz, Sonja W. , Snyder, Allison , Tartaglia, Maria Carmela , Traynor, Bryan J, Wong, Bonnie, Kornak, John , Kremers, Walter K. , Forsberg, Leah K. , Heuer, Hilary W. , Boeve, Bradley F. , Rosen, Howard J, Boxer, Adam L, Staffaroni, Adam M. , Sanderson‐Cimino, Mark , Saloner, Rowan , Casaletto, Kaitlin B. , Kramer, Joel H. , Miller, Bruce L. , Seeley, William W. , Gorno‐Tempini, Maria Luisa , Rojas, Julio C. , Sturm, Virginia E. , Appleby, Brian S. , Day, Gregory S, Vito, Alyssa De, Eldaief, Mark C. , Huey, Edward D. , Irwin, David J. , Kantarci, Kejal , Masdeu, Joseph, Onyike, Chiadi U. , Popli, Tanav A. , Tartaglia, Maria Carmela , Traynor, Bryan J. , Rosen, Howard J. , Boxer, Adam L.

Mayo Clinic

No container title available | September 22, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.09.18.26363439 | PMID 42818136 Get It

Introduction: Frontotemporal lobar degeneration (FTLD) is a devastating disease that commonly results in early onset dementia, yet its rarity and heterogeneity limit large-scale research and clinical trials. Remote monitoring via low-burden digital health tools may overcome these barriers. We evaluated clinical utility of passive smartphone monitoring in FTLD using a multi-domain mobile assessment platform. Methods: Participants were 567 adults (53% clinically normal, 21% prodromal FTLD, 26% symptomatic FTLD) who completed an in-person study visit and downloaded the ALLFTD Mobile App on their personal smartphones. The app delivered unsupervised cognitive tests and passively collected continuous data on battery percentage (proxy for smartphone use) and step count. Longitudinal follow-up included smartphone monitoring and annual in-person study visits. Primary analyses examined associations between passive smartphone features and markers of disease severity at baseline and longitudinally, and tested whether passive features added incremental value beyond app-based cognitive testing. Results: Passive smartphone features were feasible to collect and showed excellent reliability with <2 weeks of monitoring (ICCs>0.9). Features capturing smartphone use and movement demonstrated sensitivity to gold-standard clinical measures of disease severity both at baseline and longitudinally. A classification model combining passive features, the app-based cognitive composite score, and demographics detected longitudinal functional decline (AUC=0.89); passive features alone (AUC=0.84) performed comparably to a cognitive screener (AUC=0.85). Discussion: Passive smartphone monitoring is a valid, zero-burden measure of disease severity and progression in FTLD that adds modest incremental value beyond app-based cognitive testing. Findings support its use as a scalable digital endpoint in longitudinal FTLD research.
Herpesvirus genome integration in whole‐genome sequences of dementia and control cohorts
Piotrowski, Stacey L. , Allnutt, Mary Alice , Johnson, Kory, Ferrucci, Luigi, Morris, Huw, Hardy, John, Ryten, Mina, Logroscino, Giancarlo, Troncoso, Juan C. , Beach, Thomas G., Serrano, Geidy E., Cruchaga, Carlos, Ross, Owen A., Chiò, Adriano, Ding, Jinhui, Scholz, Sonja W. , Jacobson, Steven, Hardy, John , May, Patrick , Scholz, Sonja W , Hardy, John , May, Patrick , Houlden, Henry , Johnson, Kory, Tanaka, Toshiko , Ferrucci, Luigi , Ryten, Mina , Logroscino, Giancarlo , Beach, Thomas G. , Serrano, Geidy E. , Cruchaga, Carlos , Dickson, Dennis W. , Ross, Owen A. , Chiò, Adriano , Houlden, Henry , Dalgard, Clifton L. , Ding, Jinhui , Gibbs, J. Raphael , Traynor, Bryan J. , Jacobson, Steven

Mayo Clinic

Alzheimer's & Dementia | March 19, 2026 | Volume: 22 | Issue: 3 | Pages: No page available

10.1002/alz.71047 | PMID 41853978 Get It

Abstract INTRODUCTION The infectious hypothesis suggests that microbes like herpesviruses may play a role in the pathogenesis of Alzheimer's disease (AD) and other related dementias through methods that may include viral genome integration. The occurrence of herpesvirus genome integration in dementia patients has not been thoroughly characterized. METHODS Over 7500 total whole‐genome sequences from control, frontotemporal dementia/amyotrophic lateral sclerosis spectrum, Lewy body dementia (LBD), multiple system atrophy (MSA), and AD cohorts were screened for the integration of pathogen genomes using the PathSeq computational tool. RESULTS Low PathSeq scores for human herpesvirus 6 (HHV‐6) were consistent with the suspected integration of viral genome segments. The LBD and MSA cohorts had a significantly higher prevalence of this partial HHV‐6 genome integration. DISCUSSION This higher prevalence in both synucleinopathies was not noted in other herpesviruses, suggesting that the integration of HHV‐6 may play a role in a subset of these patients. Highlights Over 7500 whole‐genome sequences from controls and dementia patients were analyzed. Sequences consistent with integrated herpesviruses were identified using PathSeq. Prevalence of partial HHV‐6 integration was higher in synucleinopathies. Herpesviruses genome integration may play a role in subsets of dementia patients.
Unintended prolonged opioid use: a prospective case–control study
Hooten, W. Michael , Erickson, Darin J. , Scholz, N. , Waljee, Jennifer F., Brummett, Chad M., Jeffery, Molly M., Chawarski, Marek Cezary , Waljee, Jennifer F. , Brummett, Chad M. , Jeffery, Molly Moore

Mayo Clinic

Pain | March 9, 2026 | Volume: 167 | Issue: 6 | Pages: e180-e190

10.1097/j.pain.0000000000003945 | PMID 41800757 Get It

Abstract Appropriate short-term use of opioids in opioid-naive adults can result in unintended prolonged opioid use (UPOU) which is associated with significant morbidity and mortality. The objective of this prospective case–control study was to identify incident cases of UPOU and to compare their characteristics with patients who did not progress to UPOU. Opioid-naive adults receiving an initial opioid prescription for surgical or nonsurgical indications were recruited at 3 clinical sites. Patients progressing to UPOU (cases) were identified 90 days after the initial prescription and compared with patients who did not progress to UPOU (controls). The status of opioid use was verified using urine drug tests. The cohort included 513 cases and 517 controls. The mean (SD) patient age was 49.6 (15.3) years and 694 (67.4%) were female. In an adjusted logistic regression analysis, several patient characteristics significantly associated with UPOU included ≥2 emergency department evaluations in the past year; prior spine, joint replacement, or cataract surgery; status as a current or former smoker; daily use of over-the-counter pain medications; opioid craving; and greater pain interference. Conversely, characteristics negatively associated with UPOU included postsurgical pain as the indication for the initial opioid prescription, prior pregnancy, greater widespread body pain, and lower levels of general activity. The findings of this study offer novel insights into the behavioral pain responses and patient characteristics associated with UPOU. These results will be used to promote strategies to identify at-risk patients and to deploy interventions targeting the modifiable risk factors for UPOU.
Chromosome X-wide association study in multiple system atrophy identifies sex-differential risk loci
Ray, Anindita , Chia, Ruth , Rasheed, Memoona, Ece, Bayram, Jinhui, Ding, Walton, Ronald L., Diez-Fairen, Monica, Álvarez, Ignacio Morales, Fanciulli, Alessandra , Seppi, Mag Klaus, Duerr, Susanne, Leys, Fabian , Krismer, Florian , Sidoroff, Victoria , Pirker, Walter , Rascol, Olivier, Foubert-Samier, Alexandra, Meissner, Wassilios G, Tison, François , Barone, Paolo, Russillo, Maria Claudia, Marín-Lahoz, Juan, Kulisevsky, J, Torres, Soraya, Mir, Pablo, Periñán, María Teresa, Proukakis, C., Goh, Yee Yen, Parkkinen, Laura, Hu, Michele T, Saxon, Jennifer A. , Rollinson, Sara , Garland, Emily M. , Litvan, Irene, Alcalay, Roy N, Kwei, Kimberly , Lubbe, Steven, Mao, Qinwen, Flanagan, Margaret E, Castellani, Rudolph J, Ndayisaba, Alain , Calvo, Andrea, Canosa, Antonio, Bohannan, Ryan C., Norcliffe-Kaufmann, Lucy, Palma, Jose-Alberto, Dawson, Ted M, Albert, Marilyn S, Pletniková, Olga , Troncoso, Juan C, Lage, Carmen , Sánchez-Juan, Pascual, Serrano, Geidy E, Beach, Thomas G, Morris, Huw R, Clarimon, Jordi, Jaunmuktane, Zane, Révész, Tamás, Warner, Tom, Hardy, John A, Ryten, Mina, Ferrucci, Luigi, Topol, Eric, Torkamani, Ali, DeCasien, Alex R, Chiò, Adriano, Low, Philip, Wszolek, Zbigniew K, Dickson, Dennis W., Traynor, Bryan J, Gibbs, J Raphael, Dalgard, Clifton L, Ross, Owen A, Houlden, Henry, Scholz, Sonja W., Hardy, John , Dickson, Dennis W. , Ross, Owen A. , Houlden, Henry , Scholz, Sonja W. , Chia, Ruth , Proukakis, Christos , Dickson, Dennis W , Dalgard, Clifton L , Ross, Owen A , Houlden, Henry , Scholz, Sonja W , Hardy, John , Reynolds, Regina H. , Díez-Fairén, Mónica , Fanciulli, Alessandra , Stefanova, Nadia , Seppi, Klaus , Krismer, Florian, Zimprich, Alexander , Rascol, Olivier , Foubert‐Samier, Alexandra , Meissner, Wassilios G. , Tison, François , Traon, Anne Pavy‐Le , Pellecchia, Maria Teresa , Marín‐Lahoz, Juan , Kulisevsky, Jaime , Mir, Pablo , Chelban, Viorica , Wu, Lesley , Kobylecki, Christopher , Biaggioni, Italo , Litvan, Irene , Rubio, Ileana, Lubbe, Steven , Flanagan, Margaret E , Castellani, Rudolph J. , Khurana, Vikram , Mora, Gabriele , Floris, Gianluca , Moore, Anni K. , Norcliffe‐Kaufmann, Lucy , Palma, Jose-Alberto , Kaufmann, Horacio , Dawson, Ted M , Rosenthal, Liana S. , Pantelyat, Alexander , Troncoso, Juan C. , Infante, Jon , Serrano, Geidy E. , Beach, Thomas G. , Pástor, Pau , Albani, Diego , Clarimón, Jordi , Jaunmuktane, Zane , Frontzek, Karl , Warner, Thomas T. , Ferrucci, Luigi , Topol, Eric J. , Torkamani, Ali , DeCasien, Alex R. , Chiò, Adriano , Singer, Wolfgang , Cheshire, William P. , Wszołek, Zbigniew K. , Traynor, Bryan J. , Gibbs, J. Raphael

Mayo Clinic

Brain | February 12, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/brain/awag062 | PMID 41684229 Get It

Abstract The human X chromosome accounts for ∼5% of the genome. Despite its size, the role of X-chromosomal variants in human diseases is not well understood, mainly due to its distinct inheritance pattern and the frequent omission of sex chromosomes from genome-wide association studies. This study used whole-genome sequencing data from 888 multiple system atrophy (MSA) cases and 7128 controls to perform an X-chromosome-wide common variant association study. Our analyses revealed two sex-differential risk loci: one located at Xq28, associated with increased risk for MSA in females [index variant: rs4898389, odds ratio (OR) = 1.69, 95% confidence interval (CI) = 1.40–2.03, P-value = 2.43 × 10⁻⁸], and another at Xp22.2 within the TBL1X gene, identified in males (index variant: rs6638956, OR = 1.48, 95%CI = 1.26–1.73, P-value = 9.92 × 10⁻⁷). In the Xq28 locus, colocalization analyses pointed to FAM3A and PLXNA3 as genes of interest. These findings emphasize the vital role of sex-differential genetic factors in the pathogenesis of MSA.
Lack of epistatic interaction of SNCA with APOE in synucleinopathies
Saini, Prabhjyot, Estiar, Mehrdad A. , Krohn, Lynne , Mufti, Kheireddin , Ruskey, Jennifer A. , Asayesh, Farnaz , Laurent, Sandra B., Montplaisir, Jacques , Gagnon, Jean‐François , Désautels, Alex , Janes, Francesco , Bernardini, Andrea , Oertel, Wolfgang H. , Janzen, Annette , Figorilli, Michela , Puligheddu, Monica , Mollenhauer, Brit , Trenkwalder, Claudia , Sixel‐Döring, Friederike , Monaca, Christelle, Dijkstra, Femke , Viaene, Mineke , Abril, Beatriz, Anselmi, Victoria, Scholz, Sonja W. , Krohn, Lynne , Mufti, Kheireddin , Arnulf, Isabelle , Dauvilliers, Yves , Kemlink, David , Oertel, Wolfgang H , Kaivola, Karri , Janzen, Annette , Boeve, Brad , Rouleau, Guy Armand , Ibrahim, Abubaker , Stefani, Ambra , Hu, Michele T M , Scholz, Sonja W , Gan-Or, Ziv , Bernardini, Andrea , Janes, Francesco , Figorilli, Michela , Puligheddu, Monica , Yu, Eric , Rudakou, Uladzislau , Spiegelman, Dan , Arnulf, Isabelle , Dauvilliers, Yves , Gigli, Gian Luigi , Valente, Mariarosaria , Šonka, Karel , Plazzi, Giuseppe , Antelmi, Elena , Biscarini, Francesco , Cochen De Cock, Valérie , Heidbreder, Anna , Ferini-Strambi, Luigi , Boeve, Bradley F. , Postuma, Ronald B. , Ibrahim, Abubaker , Stefani, Ambra , Högl, Birgit , Gan‐Or, Ziv

Mayo Clinic

Brain Communications | November 17, 2025 | Volume: 7 | Issue: 6 | Pages: No page available

10.1093/braincomms/fcaf455 | PMID 41341545 Get It

Abstract Two recent studies suggested that the APOE ε4 haplotype was associated with increased α-synuclein pathology in cell and mouse models. Genetic variants in the SNCA region have strong association with Parkinson’s disease (PD), dementia with Lewy bodies (DLB) and idiopathic REM sleep behaviour disorder (iRBD), while APOE is a genetic risk determinant for only DLB. To determine if genetic-level interactions between SNCA and APOE exists that can explain the protein-level association, we investigated the genotypic interaction of APOE and SNCA in cohorts of PD, DLB and iRBD. We analysed genome-wide association study (GWAS) data from 5229 PD patients and 5480 controls, 2610 DLB patients and 1920 controls, and 1055 iRBD patients and 3667 controls. We used logistic regression interaction models across all three cohorts independently between the (i) top GWAS signals of SNCA single nucleotide polymorphisms (SNPs) and APOE haplotypes and (ii) SNP×SNP and three-way SNP interaction across the entire coding region plus 200 kb flanking each gene. No significant interactions were found to be associated with any of the synucleinopathies after correction for multiple testing. Our results do not support a role for genetic interactions between APOE and SNCA across PD, DLB and iRBD. Since the tested genetic variants affect the expression and function of these proteins, it is likely that any interactions between them do not affect the risk of PD, DLB and iRBD.
Association between Human Leukocyte Antigen Alleles and Neuropathological Outcomes in Lewy Body Disease
Gavrielatos, Marios , Heckman, Michael G. , Blumenfeld, Sophia G. , Hou, Xu , Koga, Shunsuke , Murray, Melissa E., Kasanuki, Koji , Ono, Daisuke , Fiesel, Fabienne C. , Uitti, Ryan J. , Fields, Julie A. , Kantarci, Kejal , Lowe, Val J. , Jack, Clifford R. , Ertekin‐Taner, Nilüfer , Dalgard, Clifton L., Savica, Rodolfo , Graff‐Radford, Jonathan , Petersen, Ronald C. , Reichard, R. Ross , Graff‐Radford, Neill R., Ferman, Tanis J. , Boeve, Bradley F., Wszolek, Zbigniew K., Mignot, Emmanuel, Scholz, Sonja W. , Ross, Owen A. , Koga, Shunsuke , Fiesel, Fabienne C , Ramanan, Vijay K , Kantarci, Kejal , Savica, Rodolfo , Graff-Radford, Jonathan , Petersen, Ronald C , Gan-Or, Ziv , Scholz, Sonja W , Dickson, Dennis W , Ross, Owen A , Jack, Clifford R , Heckman, Michael G , Ferman, Tanis J , Soto‐Beasley, Alexandra I. , Hou, Xu , Murray, Melissa E. , Botha, Hugo , Ramanan, Vijay K. , Gibbs, J. Raphael , Traynor, Bryan J. , Graff‐Radford, Neill R. , Boeve, Bradley F. , Springer, Wolfdieter , Gan‐Or, Ziv , Dickson, Dennis W.

Mayo Clinic

Annals of Neurology | November 7, 2025 | Volume: 99 | Issue: 2 | Pages: 492-501

10.1002/ana.78075 | PMID 41200866 Get It

Objective Lewy body disease (LBD) is a complex neurodegenerative disorder characterized by the accumulation of misfolded α‐synuclein in the brain. Neuroinflammation has long been implicated in LBD pathogenesis, and recent genetic studies in Parkinson's disease (a clinical manifestation of LBD) have shown consistent association with the human leukocyte antigen (HLA) gene complex. Here, we assessed whether variation in HLA alleles influences neuropathological burden in a neuropathologically‐defined series of LBD cases. Methods We conducted a comprehensive analysis of HLA allelic variants in a cohort of 539 LBD cases of European descent from the Mayo Clinic brain bank. High‐resolution whole‐genome sequencing was used, and the HLA alleles of each sample were called using the HLA*LA tool and assessed for association with neuropathological outcomes. Results Our analysis identified 1 significant ( P < 3.43 × 10 −5 ) and 4 suggestive ( P < 0.001) associations between certain HLA alleles and specific neuropathological outcomes in LBD, suggesting a potential role for HLA‐mediated immune mechanisms in disease progression and subtype differentiation. Specifically, HLA‐DPB1*06:01 was significantly associated with lower Lewy body counts in the parahippocampal gyrus ( P = 3.30 × 10 −5 ), with weaker and suggestive associations observed in the middle frontal ( P = 1.80 × 10 −4 ) and inferior parietal gyrus ( P = 6.33 × 10 −4 ). Additionally, although only suggestive, HLA‐DRB1*11:01 correlated with a lower Thal amyloid phase ( P = 1.56 x 10 −4 ), and HLA‐B*15:01 correlated with an increased risk of diffuse LBD ( P = 7.58 x 10 −4 ). Interpretation This study provides a detailed evaluation of the relationship between HLA alleles and LBD pathology, highlighting the importance of immune‐related genetic factors in the etiology of LBD. ANN NEUROL 2026;99:492–501
Integrating a motor domain enhances disease severity scales in an FTD‐ALS spectrum cohort
Snyder, Allison, Samra, Kiran , Wu, Tianxia, Russell, Lucy L. , Farren, Jennifer, Crook, Jody, Haselhuhn, Taryn, Porter, Katelyn, Szabo, Marcell , Duckett, Ariana, Lin, Fiona, Danielian, Laura E., Scholz, Sonja W. , Rosen, Howard J. , Rohrer, Jonathan D., Kwan, Justin , Scholz, Sonja W , Russell, Lucy L , Crook, Jody, Porter, Katelyn, Traynor, Bryan J. , Boeve, Bradley F. , Rohrer, Jonathan D.

Mayo Clinic

Alzheimer's & Dementia | October 29, 2025 | Volume: 21 | Issue: 10 | Pages: No page available

10.1002/alz.70786 | PMID 41152189 Get It

Abstract INTRODUCTION The Genetic Frontotemporal Initiative (GENFI) and Advancing Research and Treatment in Frontotemporal Lobar Degeneration (ARTFL)‐Longitudinal Evaluation of Familial Frontotemporal Dementia Subjects (LEFFTDS) Longitudinal Frontotemporal Lobar Degeneration Study (ALLFTD) consortia developed Clinical Dementia Rating (CDR)‐derived scales with a motor domain to overcome systematic underestimation of disease severity by the CDR. We calculated disease severity scores using these scales in a mixed neurodegenerative cohort and correlated them with objective motor measures. METHODS The CDR plus National Alzheimer's Coordinating Center (NACC) Frontotemporal Lobar Degeneration (FTLD), CDR + NACC FTLD‐M (Motor), and Multidomain Impairment Rating (MIR) scores and motor measures were determined and correlated in 242 participants. RESULTS Both CDR + NACC FTLD‐M and MIR showed increased disease severity scores and correlated with motor measures. These findings were held in 81 amyotrophic lateral sclerosis (ALS) participants and correlated with the Revised Amyotrophic Lateral Sclerosis Functional Rating Scale. Including a motor domain required fewer study participants in a simulated clinical trial sample size calculation. DISCUSSION With a motor domain, CDR + NACC FTLD‐M and MIR improve disease severity classification and correlate with quantitative motor assessments. This addition more fully captures the extent of symptoms across the FTD‐ALS spectrum and improves clinical trial efficiency. Highlights CDR + NACC FTLD‐M and MIR strongly correlate with objective motor measures. The enhanced scales improve disease severity classification in FTD and ALS. Greater clinical trial efficiency is achieved using these enhanced scales.
Repeat-associated ataxias in a German patient cohort analysed by targeted parallel long-read sequencing
Erdmann, Hannes , Schaub, Annalisa , Lucas, Morghan C. , Scholz, Veronika , Benet‐Pagès, Anna , Dineiger, Christine, Mayer, Veronika, Buren, Inga Van , Breithausen, Eva, Akbari, Karl, Sauer, Mayra , Krakowsky, Rosanna , Schnabel, Franziska , Dunker, Konstanze, Fabritius, Lena, Gerb, Johannes , Grabova, Denis , Möhwald, Ken , Näher, Marius, Steinmetz, Karoline , Thiessen, Franziska, Jäck, Alexander , Schreyer, Isolde, Mämecke, Larissa, Wilfling, Sibylle, Wunderlich, Gilbert , Hellenbroich, Yorck, Muhle, Kirsten, Claus, Inga, Klopstock, Thomas, Strupp, Michael, Xiong, Chengjie , Huppert, Doreen , Becker‐Bense, Sandra , Filippopulos, Filipp , Kilpert, Fabian , Kaya, Sabine, Schöberl, Florian, Neuhann, Teresa , Holinski‐Feder, Elke , Zwergal, Andreas , Abicht, Angela, Cordts, Isabell , Gerb, Johannes , Brenner, David , Xiong, Chengjie , Kilpert, Fabian , Depienne, Christel , Zwergal, Andreas , Becker, Kerstin , Mayer, Veronika, Akbari, Karl, Schneider, Christine B. , Thiessen, Franziska, Schneider-Gold, Christiane , Zittel, Simone , Petersen, Christina, Huchtemann, Tessa , Höglinger, Günter U. , Leitão, Elsa , Depienne, Christel , Abicht, Angela

Mayo Clinic

Brain | September 1, 2025 | Volume: 149 | Issue: 3 | Pages: 993-1006

10.1093/brain/awaf318 | PMID 40898875 Get It

Abstract Hereditary adult-onset ataxias are a heterogeneous group of phenotypically overlapping conditions, often caused by pathogenic expansions of short tandem repeats. Currently, 18 repeat disorders with a core phenotype of adult-onset ataxia are known. Diagnosis typically relies on sequential PCR-based methods, which are labour-intensive and lack precision. Long-read sequencing (LRS) has the potential to overcome these limitations and is currently implemented and validated in clinical genetics. Using clinical nanopore Cas9-targeted sequencing (Clin-CATS) for parallel in-depth repeat analysis, we evaluated a diagnostic cohort of 513 adult-onset ataxia patients, determining frequencies of all known repeat-associated ataxias except Spinocerebellar ataxia 4 (SCA4), as well as the carrier frequencies for autosomal-recessive disorders, RFC1 spectrum disorder and Friedreich’s ataxia (FRDA). Additionally, phenotypes of patients with established genetic diagnoses were characterized, especially those of patients living with RFC1 spectrum disorder and SCA27B. Repeat-associated ataxias were confirmed in 33.3% of cases, including rare ataxias, such as SCA10, SCA36 and SCA37, alongside as the most prevalent conditions SCA27B and RFC1 spectrum disorder. Potentially pathogenic expansions in FGF14 were identified in an additional 4.7% of patients. Testing of another 347 patients for ZFHX3 expansions linked to SCA4 did not identify any cases. Dual diagnoses were frequent, occurring in 6.4% of patients with repeat-associated ataxia. We confirmed a high RFC1 spectrum disorder carrier frequency (7.2%) and reclassified certain FXN expansions as likely non-pathogenic, resulting in a lower than estimated carrier frequency for FRDA of 0.8%. We also identified novel repeat configurations in several loci and illustrated the high heterogeneity of repeat expansions in RFC1, highlighting it as a potential source of false results when using PCR-based methods. This study underscores the diagnostic advantages of LRS for comprehensive repeat analysis and recommends its adoption as a standard in clinical genetics, replacing Southern blot and PCR-based approaches. Furthermore, based on our findings in a large patient cohort a re-evaluation of existing phenotype-genotype correlations is recommended as well as evaluating additional parameters alongside the repeat length to improve diagnostic precision of repeat analysis.
Cerebellum mitochondrial DNA copy number is increased in Parkinson’s disease
Beglarian, Talia , Tyrpak, David R. , MacKay, J. Andrew , Scholz, Sonja W. , Albert, Marilyn S. , Dawson, Ted M. , Troncoso, Juan C. , Hernandez, Dena G., Cookson, Mark R , Singleton, Andrew B., Beach, Thomas G., Hjelm, Brooke E. , MacKay, John Andrew , Scholz, Sonja W , Dawson, Ted M , Cookson, Mark , Adler, C H , Serrano, Geidy E , Hjelm, Brooke E , Gibbs, J. Raphael , Traynor, Bryan J , Rosenthal, Liana S. , Adler, Charles H. , Serrano, Geidy E. , Singleton, Andrew B., Beach, Thomas G.

Mayo Clinic

Brain Communications | August 20, 2025 | Volume: 7 | Issue: 4 | Pages: No page available

10.1093/braincomms/fcaf296 | PMID 40873892 Get It

Abstract Bioinformatics methods can be used to quantify mitochondrial DNA copy number from whole genome sequencing (WGS) data. We evaluated mitochondrial DNA copy number from human brain-derived WGS data using the fastMitoCalc tool. 341 Parkinson’s Disease cerebellum samples were compared with 74 age-matched controls from the North American Brain Expression Consortium. Parkinson’s Disease cerebellum had significantly higher mitochondrial DNA copy number compared with controls (P = 4.15e–7), and this effect was reproducible in four of five brain banks when analysis was restricted to each resource that contributed Parkinson’s Disease samples to this genetic dataset. Follow-on analyses of 128 Parkinson’s Disease cerebellum samples and 33 controls that had paired neuropathology data and clinical scores demonstrated a significant increase in mitochondrial DNA copy number with Unified Staging System for Lewy Body disorders stages and Unified Parkinson’s Disease Rating Scale (off meds) motor scores. Analysis of Lewy Body scores from ten brain regions showed cerebellum mitochondrial DNA copy number increased upon pathological infestation of α-synuclein aggregates in the brainstem and limbic system but did not increase after late-stage neocortical involvement. This genetics dataset supports previous observations of cerebellum activation in Parkinson’s Disease and suggests mitochondrial DNA copy number may increase to support this regional activation as a compensatory mechanism to pathology or motor symptoms.
Implications and opportunities regarding biological frameworks in overt and prodromal dementia with Lewy bodies
Goldman, Jennifer G. , Leverenz, James B., Blanc‬, ‪Frederic, Halliday, Glenda M. , Kantarci, Kejal, Lewis, Simon J.G. , Medsger, Helen Bundy, O’Brien, John T. , Scholz, Sonja W. , Ikeda, Manabu , Kantarci, Kejal , Blanc, Frédéric , O'Brien, John Tiernan , Halliday, Glenda , Goldman, Jennifer G , Scholz, Sonja W , Lewis, Simon J G , Kantarci, Kejal , Boeve, Bradley F. , Galasko, Douglas , Taylor, John‐Paul , Galvin, James E. , Leverenz, James B. , Lemstra, Afina W. , Leroi, Iracema , Litvan, Irene , Aarsland, Dag , McKeith, Ian G. , Taylor, Angela E.

Mayo Clinic

Alzheimer's & Dementia | July 20, 2025 | Volume: 21 | Issue: 7 | Pages: No page available

10.1002/alz.70470 | PMID 40684248 Get It

Abstract Dementia with Lewy bodies (DLB), a progressive neurodegenerative disease with heterogeneous clinical presentations, greatly impacts patients, caregivers, and society. Despite its frequency, diagnosing and treating DLB remains challenging. Advances in in vivo biomarker assays reflecting underlying pathology are improving disease identification, diagnostic accuracy, and therapeutic development for biologically targeted, disease‐modifying agents. Consequently, definitions of Alzheimer's disease and Parkinson's disease (PD) have shifted to focus on pathological changes occurring before clinical features, with proposed frameworks for detecting pathological amyloid and tau, neurodegeneration, and other markers (National Institute on Aging‐Alzheimer's Association) and alpha‐synucleinopathy and dopaminergic degeneration (Neuronal α‐synuclein Disease Integrated Staging System, SynNeurGe). The biological frameworks, particularly those related to alpha‐synuclein (α‐synuclein), have sparked debate about unifying DLB and PD under a single pathobiologic disease. This paper discusses the implications of these biological frameworks for the DLB community, addressing topics regarding multiple pathologies and neurochemical systems, clinical heterogeneity, and functional impairment, and exploring the potential impact on clinical trials and care. Highlights DLB is a progressive neurodegenerative disease with varied clinical presentations. Diagnosing and treating DLB remains challenging despite its frequency. Biological frameworks are reshaping Alzheimer's and Parkinson's definitions. In vivo biomarkers are improving DLB identification and diagnostic accuracy. Debate exists regarding unifying DLB and Parkinson's under one pathobiology.